BR0316724A - Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas - Google Patents
Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticasInfo
- Publication number
- BR0316724A BR0316724A BR0316724-0A BR0316724A BR0316724A BR 0316724 A BR0316724 A BR 0316724A BR 0316724 A BR0316724 A BR 0316724A BR 0316724 A BR0316724 A BR 0316724A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical compositions
- manufacture
- preparation
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTOS, USO DE UM OU MAIS COMPOSTOS, E, PROCESSO PARA A FABRICAçãO DE COMPOSIçõES FARMACêUTICAS". A invenção se relaciona a ésteres de ácido sulfâmico inédito e seu uso como ingredientes ativos na preparação de composições farmacêuticas. A invenção também se refere a aspectos relacionados incluindo os processos para a preparação dos compostos, composições farmacêuticas contendo um ou mais daqueles compostos e especialmente seu uso como antagonistas de receptor de endotelina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0213601 | 2002-12-02 | ||
EP03778307A EP1569914B1 (en) | 2002-12-02 | 2003-11-10 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
PCT/EP2003/012502 WO2004050640A1 (en) | 2002-12-02 | 2003-11-10 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316724A true BR0316724A (pt) | 2005-10-18 |
Family
ID=32405666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316724-0A BR0316724A (pt) | 2002-12-02 | 2003-11-10 | Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7452896B2 (pt) |
EP (1) | EP1569914B1 (pt) |
JP (1) | JP4769460B2 (pt) |
KR (1) | KR101063042B1 (pt) |
CN (1) | CN100379730C (pt) |
AT (1) | ATE423103T1 (pt) |
AU (1) | AU2003285321B2 (pt) |
BR (1) | BR0316724A (pt) |
CA (1) | CA2507334C (pt) |
DE (1) | DE60326263D1 (pt) |
ES (1) | ES2320649T3 (pt) |
IL (1) | IL168836A (pt) |
MX (1) | MXPA05005793A (pt) |
NO (1) | NO20052520L (pt) |
NZ (1) | NZ540937A (pt) |
RU (1) | RU2329255C2 (pt) |
WO (1) | WO2004050640A1 (pt) |
ZA (1) | ZA200505109B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100739367B1 (ko) | 2004-07-14 | 2007-07-16 | 크리스탈지노믹스(주) | 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물 |
TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
FR2878523B1 (fr) * | 2004-11-30 | 2007-09-14 | Oreal | Nouveaux derives sulfamides et leur utilisation cosmetique |
US7887824B2 (en) | 2004-11-30 | 2011-02-15 | L'oreal | Sulfamide derivatives and cosmetic use thereof |
DE602006017071D1 (de) * | 2005-01-25 | 2010-11-04 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von herzkrankheiten |
US20100100372A1 (en) * | 2007-01-26 | 2010-04-22 | Panasonic Corporation | Stereo encoding device, stereo decoding device, and their method |
US20100035865A1 (en) * | 2007-04-03 | 2010-02-11 | Pfizer Inc | Sulfonamides and Pharmaceutical Compositions Thereof |
MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
EP2331513A1 (en) * | 2008-08-12 | 2011-06-15 | Cadila Healthcare Limited | Process for preparation of bosentan |
DK3300729T3 (da) | 2008-08-13 | 2020-01-20 | Actelion Pharmaceuticals Ltd | Terapeutiske sammensætninger indeholdende macitentan |
CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-(4-溴苯基)-6-[2-[(5-溴-2-嘧啶基)氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
EP3719013B1 (en) * | 2017-11-21 | 2023-01-04 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Pyrimidine sulfamide derivative and preparation method and medical application thereof |
CN108997223B (zh) * | 2018-08-09 | 2020-06-30 | 浙江先锋科技股份有限公司 | 5-(4-溴苯基)-4,6-二氯嘧啶的制备方法 |
CN109232546B (zh) * | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
RU2763899C1 (ru) * | 2021-03-26 | 2022-01-11 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Натриевая соль 4-{ 2-[2-(4-гидрокси-3-метоксифенил)-винил]-6-этил-4-оксо-5-фенил-4H-пиримидин-1-ил} -бензсульфамида, обладающая противоопухолевым действием |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1549494A (pt) | 1967-10-31 | 1968-12-13 | ||
DE2801584A1 (de) * | 1978-01-14 | 1979-07-19 | Bayer Ag | Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
IL111959A (en) | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
TW313568B (pt) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
JP3087968B2 (ja) | 1995-12-20 | 2000-09-18 | 山之内製薬株式会社 | アリールエテンスルホンアミド誘導体及びその医薬組成物 |
TWI284642B (en) * | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
EP1345920B1 (en) * | 2000-12-18 | 2006-04-12 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
-
2003
- 2003-11-10 NZ NZ540937A patent/NZ540937A/en unknown
- 2003-11-10 KR KR1020057008632A patent/KR101063042B1/ko not_active IP Right Cessation
- 2003-11-10 ES ES03778307T patent/ES2320649T3/es not_active Expired - Lifetime
- 2003-11-10 DE DE60326263T patent/DE60326263D1/de not_active Expired - Lifetime
- 2003-11-10 BR BR0316724-0A patent/BR0316724A/pt not_active IP Right Cessation
- 2003-11-10 CN CNB2003801034698A patent/CN100379730C/zh not_active Expired - Fee Related
- 2003-11-10 MX MXPA05005793A patent/MXPA05005793A/es active IP Right Grant
- 2003-11-10 AT AT03778307T patent/ATE423103T1/de active
- 2003-11-10 RU RU2005120769/04A patent/RU2329255C2/ru not_active IP Right Cessation
- 2003-11-10 WO PCT/EP2003/012502 patent/WO2004050640A1/en active Application Filing
- 2003-11-10 JP JP2004556119A patent/JP4769460B2/ja not_active Expired - Fee Related
- 2003-11-10 CA CA2507334A patent/CA2507334C/en not_active Expired - Fee Related
- 2003-11-10 US US10/537,400 patent/US7452896B2/en not_active Expired - Fee Related
- 2003-11-10 EP EP03778307A patent/EP1569914B1/en not_active Expired - Lifetime
- 2003-11-10 AU AU2003285321A patent/AU2003285321B2/en not_active Ceased
-
2005
- 2005-05-25 NO NO20052520A patent/NO20052520L/no not_active Application Discontinuation
- 2005-05-26 IL IL168836A patent/IL168836A/en active IP Right Grant
- 2005-06-23 ZA ZA200505109A patent/ZA200505109B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ540937A (en) | 2008-06-30 |
EP1569914A1 (en) | 2005-09-07 |
JP2006509775A (ja) | 2006-03-23 |
CA2507334C (en) | 2013-05-07 |
MXPA05005793A (es) | 2005-08-16 |
JP4769460B2 (ja) | 2011-09-07 |
ATE423103T1 (de) | 2009-03-15 |
NO20052520L (no) | 2005-06-27 |
US7452896B2 (en) | 2008-11-18 |
KR101063042B1 (ko) | 2011-09-07 |
CA2507334A1 (en) | 2004-06-17 |
DE60326263D1 (de) | 2009-04-02 |
AU2003285321B2 (en) | 2010-04-08 |
CN100379730C (zh) | 2008-04-09 |
RU2329255C2 (ru) | 2008-07-20 |
ZA200505109B (en) | 2007-04-25 |
KR20050086625A (ko) | 2005-08-30 |
RU2005120769A (ru) | 2006-02-27 |
ES2320649T3 (es) | 2009-05-27 |
EP1569914B1 (en) | 2009-02-18 |
CN1711248A (zh) | 2005-12-21 |
IL168836A (en) | 2010-12-30 |
US20070167472A1 (en) | 2007-07-19 |
NO20052520D0 (no) | 2005-05-25 |
AU2003285321A1 (en) | 2004-06-23 |
WO2004050640A1 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
NO20052520L (no) | Nye sulfamider | |
ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
BR0116237A (pt) | Compostos, composições farmacêuticas, uso de qualquer um ou mais compostos, e, processo para a manufatura de composições farmacêuticas | |
BRPI0408681A (pt) | compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos | |
NO20042844L (no) | 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister | |
NO20034230D0 (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
NO20032905L (no) | Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister | |
SE0002102D0 (sv) | Chemical compound | |
BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
WO2004026836A3 (en) | 1-pyridin-4-yl-urea derivatives | |
DOP2002000512A (es) | Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
ATE383345T1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
BR0211729A (pt) | Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas | |
TW200628467A (en) | Novel sulfamides | |
WO2002024665A8 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
MXPA03000430A (es) | Nuevas arileteno-sulfonamidas. | |
MXPA02006250A (es) | Derivados de butino diol. | |
UY26971A1 (es) | Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos | |
BRPI0412425A (pt) | compostos, intermediários, composições farmacêuticas, uso de um ou mais compostos, e, processo para a manufatura de composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014. |